Resumen de: GB2613032A

A system and method of calibrating a model used in a device for non-invasive in vivo measurement of an analyte concentration using Raman spectroscopy. The device comprises an optical source for providing an optical signal and an optical detector to receive a Raman scattered optical output. The method (Fig.2) comprises, in response to the laser source being directed to a user’s skin 213, gathering Raman scattered radiation from the user’s skin and based on that, calibrating the model based on reference data and the received Raman spectra over an extended period of days. Once the model is calibrated, storing the model for use. The calibration period can be 14 days or 20 days or between 20 and 28 days. The method may comprise receiving reference data from an invasive blood glucose monitoring device.

Resumen de: EP4183326A1

Method and System for providing a signal from an insulin pump, artificial pancreas, or another insulin delivery device as a source of information for improving the accuracy of a continuous glucose sensor (CGS). The effect of using insulin information to enhance sensor accuracy is most prominent at low blood glucose levels, i.e. in the hypoglycemic range, which is critical for any treatment. A system for providing a filtering/state estimation methodology that may be used to determine a glucose state estimate at time t-τ. The estimation may be extrapolated to some future time t and then the extrapolated value is used to extract the blood glucose component. The blood glucose component of the extrapolation and the output of the CGS are weighted and used to estimate the blood glucose level of a subject.

Resumen de: WO2016161254A1

Methods and systems are disclosed analyzing a glucose level of a person having diabetes. The method, in at least one example, comprises receiving into a computing device a plurality of measured glucose values from a continuous glucose monitoring system coupled to a person having diabetes, analyzing the plurality of measured glucose values with a probability analysis tool on the computing device to determine a glucose threshold (g lc ), and a boundary (g ρ ) glucose value at a probability threshold where the person having diabetes requires at least a predetermined insulin dose, and comparing, with the computing device, the boundary glucose value (g ρ ) to the glucose threshold (g lc ), wherein if the boundary glucose value (g ρ ) is greater than the glucose threshold (g lc ) then the computing device performs an alert on a user interface.

Resumen de: WO2023086482A1

A device for delivering medicament to a user is disclosed. The device comprises a reservoir for storing medicament; an infusion catheter fluidly communicating with the reservoir to deliver the medicament into a subcutaneous layer of the user; a pump fluidly communicating with the reservoir and infusion catheter for pumping the medicament from the reservoir though the infusion catheter; an introducer needle movable within the infusion catheter, the introducer needle configured to facilitate (a) insertion of the infusion catheter into a subcutaneous layer of the user and (b) retraction of the introducer needle after insertion of the infusion catheter to enable delivery of medicament through the infusion catheter; and a sensor for continuously monitoring glucose level in the user, wherein the sensor is configured to (a) engage the introducer needle and/or the infusion catheter and (b) simultaneously advance along with the infusion catheter during the insertion into the subcutaneous layer of the user by the introducer needle.

Resumen de: WO2023084453A1

The present invention relates to a method and system for determining risk data (1) concerning injury in a user's foot, for designing and developing customised insoles for the early management of biomechanical alterations in diabetic patients, supported by a telemedicine platform and 15 embedded digital modules with protocols and software applications, for acquiring and integrating patient information by means of commercial specialised electronic devices integrated into the platform and which provided step-by-step assistance to an expert (8) for the smart automated design and remote production of customised therapeutic insoles adapted to the size and morphology of each user with diabetic foot syndrome.

Resumen de: WO2023086232A1

In some examples, a system for monitoring glucose includes processing circuitry and a glucose monitor comprising one or more monitor electrodes and one or more working electrodes, wherein a first chemistry stack is disposed on at least one of the monitor electrode(s) and a second chemistry stack is disposed on at least one of the working electrode(s). The processing circuitry may be configured to measure one or more calibration values of an operating parameter of the monitor electrode(s), retrieve one or more pre-calibration values of the operating parameter of the monitor electrode(s), wherein the pre-calibration value(s) were measured before the calibration value, determine one or more delta values using the calibration value(s) and the pre-calibration value(s), and calibrate glucose values sensed by the working electrode(s) using the delta value(s).

Resumen de: WO2023086980A1

Described herein are preserved formulations of insulin-Fc fusions. The formulations include insulin-Fc fusions having prolonged pharmacokinetic and pharmacodynamic profiles sufficient for once weekly administration in the treatment of diabetes and are sufficiently stable to allow for storage and use without unacceptable loss of chemical or physical stability.

Resumen de: WO2023086632A1

A glucose monitoring system comprising a sensor control device comprising an analyte sensor coupled with sensor electronics, the sensor control device configured to transmit data indicative of an analyte level of a subject, and a reader device. The reader device comprises a wireless communication circuitry configured to receive the data indicative of the analyte level and a glycated hemoglobin level for the subject, a non- transitory memory, and at least one processor communicatively coupled to the non- transitory memory and the analyte sensor and configured: calculate a plurality of personalized glucose metrics for the subject using at least one physiological parameter and at least one of the received data indicative of the analyte level or the received glycated hemoglobin level, and a display, on a display of the reader device, a report comprising a plurality of interfaces including at least two or more of the received data indicative of the analyte level, the received glycated hemoglobin level, or the calculated plurality of personalized glucose metrics, wherein the plurality of interfaces comprising the report are based on a user type.

Resumen de: US2023149639A1

A syringe, having a front portion carrying a hollow, axially extending needle, a container, running from said front portion and forming a container rear end portion, a plunger, extending and being movable axially in the container, the needle rear end being in fluid connection with the container and the plunger being arranged to suck liquid, e.g. a liquid comprising insulin, through the needle when drawn away from the needle and to discharge liquid through the needle when pushed towards the needle, the plunger having a piston portion, turned to the needle rear end, and a coupling portion arranged to co-act with the piston portion for moving the piston portion in the container.

Resumen de: US2023148917A1

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

Resumen de: US2023148916A1

In some examples, a system for monitoring glucose includes processing circuitry and a glucose monitor comprising one or more monitor electrodes and one or more working electrodes, wherein a first chemistry stack is disposed on at least one of the monitor electrode(s) and a second chemistry stack is disposed on at least one of the working electrode(s). The processing circuitry may be configured to measure one or more calibration values of an operating parameter of the monitor electrode(s), retrieve one or more pre-calibration values of the operating parameter of the monitor electrode(s), wherein the pre-calibration value(s) were measured before the calibration value, determine one or more delta values using the calibration value(s) and the pre-calibration value(s), and calibrate glucose values sensed by the working electrode(s) using the delta value(s).

Resumen de: US2023148910A1

A lifestyle coaching system for lifestyle intervention in disease management is provided. The lifestyle coaching system detects a patient performing various lifestyle activities, such as a workout or stress-inducing activity, as part of determining and optimizing real time or near-real time coaching output that is displayed to a patient via a user device. The provided lifestyle coaching system is able to detect a start and end time of each of the patient's workouts despite receiving the patient's heart rate data at a low sampling rate from a fitness tracking device by combining the low sample rate heart rate data with secondary factors indicative of patient working out. The provided lifestyle coaching system is also able to detect when an elevated heart rate of a patient is due to stress rather than exercise.

Resumen de: AU2021358022A1

A delivery device for delivering medicament, such as insulin, to a patient includes a housing and a base enclosing an inner cavity. Enclosed within the housing is a reservoir for containing a medicament, a delivery mechanism for delivering the medicament to the patient, and a pump in fluid communication with the reservoir and delivery mechanism. The base has an integrally formed fluid channel covered by a flexible membrane in fluid communication with the reservoir and the delivery mechanism. A peristaltic pump mechanism includes a cam assembly having a plurality of cams and cam follower assembly with a plurality of protrusions to sequentially engaging the flexible membrane to advance the fluid through fluid channel.

Resumen de: AU2023202712A1

An encapsulation device system for therapeutic applications such as but not limited to regulating blood glucose. The system may comprise an encapsulation device with a first oxygen sensor integrated inside the device and a second oxygen sensor disposed on an outer surface of the device, wherein the sensors allow for real-time measurements (such as oxygen levels) related to cells (e.g., islet cells, stem cell derived beta cells, etc.) housed in the encapsulation device. The system may also feature an exogenous oxygen delivery system operatively connected to the encapsulation device via a channel, wherein the exogenous oxygen delivery system is adapted to deliver oxygen to the encapsulation device.

Resumen de: AU2023202651A1

The present disclosure relates to systems, devices and methods for receiving biosensor data acquired by a medical device, e.g., relating to glucose concentration values, and controlling the access and distribution of that data. In some embodiments, systems and methods are disclosed for monitoring glucose levels, displaying data relating to glucose values and metabolic health information, and controlling distribution of glucose data between applications executing on a computer, such as a smart phone. In some embodiments, systems and methods are disclosed for controlling access to medical data such as continuously monitored glucose levels, synchronizing health data relating to glucose levels between multiple applications executing on a computer, and/or encrypting data.

Resumen de: AU2023202630A1

Systems, methods, and devices provide alarms and alerts in an on-body networked diabetes management system. Methods may include receiving glucose sensor data from a continuous glucose monitor and determining a dosage of insulin delivery based at least in part on the glucose sensor data. The method may include detecting an alarm or alert condition, and sending a wireless communication regarding the alarm or alert condition to a remote user-interface device. The method may include triggering an audible, visual, or haptic alarm or alert on the insulin delivery device unless an acknowledgement of the alarm or alert condition is received within a predetermined period of time.

Resumen de: US2023154625A1

Method and system including displaying a first representation of a medication treatment parameter profile, displaying a first representation of a physiological profile associated with the medication treatment parameter profile, detecting a modification to a segment of the medication treatment parameter profile, displaying a modified representation of the medication treatment parameter profile and the physiological profile based on the detected modification to the segment of the medication treatment parameter profile, modifying an attribute of the first representation of the medication treatment parameter profile, and modifying an attribute of the first representation of the physiological profile are provided.

Resumen de: WO2022011345A1

This invention is directed to towards methods of identifying a subject with insulin resistance. For example, this invention is drawn to adjusting C-peptide urinary excretion rate for average glucose concentration to identify a subject with insulin resistance.

Resumen de: WO2023081239A1

A glucose level control system (GLCS) may be configured to determine a long-acting insulin dose recommendation based at least in part on a therapy of fast-acting insulin provided to a subject during a therapy period. The GLCS may be configured to operate in multiple operating modes with each operating mode configured to provide glucose control therapy for a different glycemic dysregulation condition (e.g., type-1 or type-2 diabetes). The GLCS may be configured to determine a recommended medicament dose based at least in part on therapy data and/or user-specified medicament related inputs, which may include qualitative meal announcements. The dose of medicament may be modified by the GLCS before the subject experiences a hypoglycemic event. The GLCS may generate a therapy management data set and perform a therapy management support process including generation of an excursion dosing threshold value or a backup therapy protocol.

Resumen de: WO2023081734A1

Certain aspects of the present disclosure relate to methods and systems for predicting glycemic events in a patient induced as a result of physical activity. In certain aspects, a method includes monitoring a plurality of analytes of the patient continuously during a time period to obtain analyte data, the plurality of analytes including at least glucose and lactate. The method further includes processing the analyte data from the time period to determine an intensity level of physical activity engaged by the patient during the time period. The method further includes generating a glycemic event prediction using at least the analyte data for the plurality of analytes and the determination of physical activity intensity. The method further includes generating one or more recommendations for treatment for the patient based, at least in part, on the glycemic event prediction.

Resumen de: WO2023080536A1

An enzyme-free blood glucose sensor and a manufacturing method therefor are disclosed. The enzyme-free blood glucose sensor comprises: a substrate; an insulating layer deposited and formed on the substrate; a porous carbon electrode deposited and formed on the insulating layer; a metal material region formed on at least a portion of the surface of the porous carbon electrode; and a palladium electrode deposited and formed on the insulating layer to be spaced apart from the porous carbon electrode, wherein in the palladium electrode, a negative voltage is applied to locally increase the concentration of hydroxide ions around the palladium electrode, and a current signal difference according to glucose concentration can be measured by using the metal material region, thereby measuring blood glucose.

Resumen de: US2023146456A1

Systems and methods are described that provide a dynamic reporting functionality that can identify important information and dynamically present a report about the important information that highlights important findings to the user. The described systems and methods are generally described in the field of diabetes management, but are applicable to other medical reports as well. In one implementation, the dynamic reports are based on available data and devices. For example, useless sections of the report, such as those with no populated data, may be removed, minimized in importance, assigned a lower priority, or the like.

Resumen de: US2023141293A1

An insulin pump bolus infusion control method. A control module of a pump body controls the pump body to start a bolus infusion control mode after receiving a function starting signal; in the bolus infusion control mode, a bolus key of a control terminal or a bolus key of an insulin pump body sends an infusion dosage signal to the control module by means of one or more operations; if the control module receives a confirmation signal within a predetermined period of time, then the control module controls the pump body to start bolus infusion; and if the control module receives a cancellation signal or does not receive the confirmation signal within a predetermined period of time, then the control module controls the pump body to exit the bolus infusion mode. Using the method enables an insulin pump to execute a more reasonable control when carrying out the bolus infusion, i.e., starting, setting and implementation of the bolus infusion, and enables a simple and quick operation.

Resumen de: US2023145330A1

Disclosed herein are techniques related to glucose estimation without continuous glucose monitoring. In some embodiments, the techniques may involve receiving input data associated with a user. The input data may comprise discrete blood glucose measurement data associated with the user, activity data associated with the user, contextual data associated with the user, or a combination thereof. The techniques may also involve using an estimation model and the input data associated with the user to generate one or more estimated blood glucose values associated with the user.

Resumen de: US2023148312A1

The subject of the invention is a device for non-invasive blood glucose concentration measurement, comprising a central control system (4), a scattering module (1) and an electronic control system (2) of the scattering module (1) connected to it. The electronic control system (2) of the scattering module (1) is connected to the central control system (4). The scattering module (1) comprises a detection element (28) and a coherent radiation source (14) connected to the control system of the coherent radiation source (13). The device is characterized in that it further comprises a transmission module (7) and an electronic control system (8) of the transmission module (7) connected to it, connected to the central control system (4). The device further comprises a proximity sensor (12), connected to the central control system (4). The device comprises an optical fiber probe (11) comprising an emitting optical fiber (15) and a measuring optical fiber (18). The emitting optical fiber (15) is connected to a coherent radiation source (14). The measuring optical fiber (18) is connected to a detection element (28). The emitting optical fiber (15) and the measuring optical fiber (18) are parallel to each other within the optical fiber probe (11). The emitting optical fiber (15) and the measuring optical fiber (18) have a numerical aperture larger or equal to 0.5.